VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma.

被引：0
|
作者：
Alexaman, R [1 ]
Wang, LM [1 ]
Weber, DM [1 ]
Delasalle, KB [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
210
引用
收藏
页码：64A / 64A
页数：1
相关论文
共 50 条
  • [1] Thalidomide and dexamethasone in newly diagnosed multiple myeloma.
    McHugh, Johnny
    O'Ceallaigh, Cathal
    Keane, Colm
    Otridge, Brian W.
    O'Gorman, Peter
    BLOOD, 2006, 108 (11) : 370B - 370B
  • [2] Thalidomide and dexamethasone in newly diagnosed multiple myeloma.
    McHugh, J
    Keane, C
    Otridge, BW
    Thornton, P
    O'Gorman, P
    BLOOD, 2005, 106 (11) : 380B - 380B
  • [3] VELCADE CYTOXAN DEXAMETHASOE (VCD) OR VELCADE THALIDOMIDE DEXAMETHASONE (VTD) INDUCTION REGIMENS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA - WHICH REGIMEN SHOULD WE PREFER?
    Leiba, M.
    Freidman, T.
    Leiba, R.
    Kedmi, M.
    Nagler, A.
    Avigdor, A.
    HAEMATOLOGICA, 2012, 97 : 347 - 347
  • [4] Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma
    Meletios A Dimopoulos
    Efstathios Kastritis
    Nature Clinical Practice Oncology, 2008, 5 : 690 - 691
  • [5] Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (12): : 690 - 691
  • [6] Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
    Lee, Yoo Jin
    Moon, Joon Ho
    Sohn, Sang Kyun
    Kim, Seok Jin
    Jung, Sung-Hoon
    Lee, Je-Jung
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Lee, Won Sik
    Lee, Ji Hyun
    Bae, Sung Hwa
    Kim, Min Kyoung
    Lee, Ho Sup
    Kim, Kihyun
    Min, Chang-Ki
    BONE MARROW TRANSPLANTATION, 2019, 54 (12) : 2051 - 2059
  • [7] Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
    Yoo Jin Lee
    Joon Ho Moon
    Sang Kyun Sohn
    Seok Jin Kim
    Sung-Hoon Jung
    Je-Jung Lee
    Jae-Cheol Jo
    Ho-Jin Shin
    Won Sik Lee
    Ji Hyun Lee
    Sung Hwa Bae
    Min Kyoung Kim
    Ho Sup Lee
    Kihyun Kim
    Chang-Ki Min
    Bone Marrow Transplantation, 2019, 54 : 2051 - 2059
  • [8] VTD (Velcade, thalidomide, dexamethasone) represents an active induction regimen for patients with multiple myeloma
    Drach, J.
    Odelga, V.
    Ackermann, J.
    Sagaster, V.
    Kaufmann, H.
    Worel, N.
    Rabitsch, W.
    Kalhs, P.
    Zielinski, C.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S183 - S183
  • [9] Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma
    Lee, Yoojin
    Kim, Kihyun
    Sohn, Sang Kyun
    Back, Dongwon
    Moon, Joon Ho
    Lee, Je-Jung
    Jo, Jae-Cheol
    Lee, Won-Sik
    Shin, Ho-Jin
    Kim, Sung-Hyun
    Lee, Ji Hyun
    Bae, Sung Hwa
    Kim, Min Kyoung
    Lee, Ho Sup
    Min, Chang-Ki
    BLOOD, 2018, 132
  • [10] VTD regimen (velcade plus thalidomide plus dexamethasone) - Effective and feasible therapy of refractory/relapsed multiple myeloma
    Gregora, E.
    Pour, L.
    Pavlicek, P.
    Kozak, T.
    Hajek, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 158 - 158
12345